Evoke Wealth’s Novo Nordisk NVO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $543K | Buy |
7,868
+2,404
| +44% | +$166K | 0.01% | 323 |
|
|
2025
Q1 | $386K | Buy |
5,464
+198
| +4% | +$14K | 0.01% | 308 |
|
|
2024
Q4 | $453K | Buy |
5,266
+19
| +0.4% | +$1.63K | 0.01% | 279 |
|
|
2024
Q3 | $625K | Buy |
+5,247
| New | +$625K | 0.02% | 225 |
|
|
2024
Q2 | – | Sell |
-4,517
| Closed | -$584K | – | 299 |
|
|
2024
Q1 | $584K | Buy |
+4,517
| New | +$584K | 0.02% | 225 |
|
|
2023
Q4 | – | Sell |
-3,053
| Closed | -$278K | – | 268 |
|
|
2023
Q3 | $278K | Buy |
3,053
+279
| +10% | +$25.4K | 0.01% | 309 |
|
|
2023
Q2 | $225K | Sell |
2,774
-34
| -1% | -$2.75K | 0.01% | 323 |
|
|
2023
Q1 | $225K | Buy |
+2,808
| New | +$225K | 0.01% | 313 |
|
|
2022
Q4 | – | Sell |
-1,310
| Closed | -$65K | – | 873 |
|
|
2022
Q3 | $65K | Sell |
1,310
-292
| -18% | -$14.5K | ﹤0.01% | 479 |
|
|
2022
Q2 | $89K | Buy |
1,602
+2
| +0.1% | +$111 | ﹤0.01% | 427 |
|
|
2022
Q1 | $90K | Sell |
1,600
-118
| -7% | -$6.64K | ﹤0.01% | 446 |
|
|
2021
Q4 | $96K | Hold |
1,718
| – | – | ﹤0.01% | 452 |
|
|
2021
Q3 | $82K | Buy |
1,718
+290
| +20% | +$13.8K | ﹤0.01% | 450 |
|
|
2021
Q2 | $60K | Hold |
1,428
| – | – | ﹤0.01% | 506 |
|
|
2021
Q1 | $49K | Buy |
1,428
+788
| +123% | +$27K | ﹤0.01% | 457 |
|
|
2020
Q4 | $22K | Hold |
640
| – | – | ﹤0.01% | 489 |
|
|
2020
Q3 | $22K | Sell |
640
-4
| -0.6% | -$138 | ﹤0.01% | 466 |
|
|
2020
Q2 | $21K | Buy |
644
+4
| +0.6% | +$130 | ﹤0.01% | 457 |
|
|
2020
Q1 | $19.5K | Hold |
640
| – | – | ﹤0.01% | 440 |
|
|
2019
Q4 | $18.5K | Sell |
640
-9,808
| -94% | -$284K | ﹤0.01% | 604 |
|
|
2019
Q3 | $270K | Buy |
+10,448
| New | +$270K | 0.03% | 217 |
|